GoodRx (NASDAQ:GDRX) Price Target Lowered to $8.00 at Wells Fargo & Company

GoodRx (NASDAQ:GDRX - Get Free Report) had its price target lowered by equities research analysts at Wells Fargo & Company from $9.00 to $8.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Wells Fargo & Company's price target would indicate a potential upside of 71.31% from the stock's current price.

Several other equities analysts have also recently commented on the company. Morgan Stanley reduced their target price on GoodRx from $7.00 to $6.00 and set an "equal weight" rating for the company in a research report on Tuesday, December 17th. KeyCorp cut their price objective on GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. Mizuho initiated coverage on shares of GoodRx in a research report on Wednesday, December 4th. They issued a "neutral" rating and a $5.00 price objective on the stock. Citigroup dropped their target price on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating for the company in a research report on Friday, January 10th. Finally, Barclays cut their price target on shares of GoodRx from $10.00 to $6.00 and set an "overweight" rating for the company in a research note on Monday, November 11th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, GoodRx presently has an average rating of "Moderate Buy" and an average target price of $8.18.

Remove Ads

GoodRx Price Performance

NASDAQ GDRX traded down $0.18 on Friday, hitting $4.67. The stock had a trading volume of 2,736,144 shares, compared to its average volume of 1,377,821. The firm has a 50-day moving average of $4.72 and a 200-day moving average of $5.70. The company has a market capitalization of $1.78 billion, a price-to-earnings ratio of -155.67, a price-to-earnings-growth ratio of 2.46 and a beta of 1.28. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. GoodRx has a 52-week low of $4.09 and a 52-week high of $9.26.

Institutional Investors Weigh In On GoodRx

A number of hedge funds have recently made changes to their positions in GDRX. National Bank of Canada FI grew its holdings in shares of GoodRx by 34.9% during the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock valued at $39,000 after purchasing an additional 2,151 shares during the last quarter. Gotham Asset Management LLC boosted its position in GoodRx by 31.0% during the fourth quarter. Gotham Asset Management LLC now owns 17,677 shares of the company's stock valued at $82,000 after buying an additional 4,182 shares during the period. Gagnon Securities LLC grew its stake in shares of GoodRx by 9.9% during the fourth quarter. Gagnon Securities LLC now owns 69,867 shares of the company's stock valued at $325,000 after buying an additional 6,266 shares during the last quarter. Swiss National Bank increased its holdings in shares of GoodRx by 4.1% in the fourth quarter. Swiss National Bank now owns 161,400 shares of the company's stock worth $751,000 after buying an additional 6,400 shares during the period. Finally, Fortem Financial Group LLC lifted its stake in shares of GoodRx by 7.2% in the 4th quarter. Fortem Financial Group LLC now owns 119,179 shares of the company's stock valued at $554,000 after acquiring an additional 7,996 shares during the last quarter. 63.77% of the stock is currently owned by institutional investors.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.